A completely different treatment approach is offered by antisense strategies that enable control of disease‐associated genes through interaction with mRNA.28, 29, 30, 31, 32 In theory, any disease associated with a well‐defined genetic aberration is amenable to mRNA intervention, and antisense systems allowing specific suppression of BCR‐ABL1 mRNA rapidly became a potential treatment alternative for patients with CML. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.